Sarepta Therpeutics and Genethon have signed a research collaboration agreement to jointly develop a gene therapy for Duchenne muscular dystrophy (DMD). Created by the AFM-Telethon, the French Muscular Dystrophy Association, Genethon is a nonprofit organization that specializes in the discovery and development of drugs for orphan genetic…
News
Researchers at Saint Louis University found that a nuclear receptor called REV-ERB is an important regulator of different steps in the process of muscle cell regeneration. According to the study “Rev-Erb co-regulates muscle regeneration via tethered interaction with the NF-Y cistrome,” which was featured in the journal Molecular…
The U.S. Food and Drug Administration has granted RASRx1902 orphan drug status to treat Duchenne muscular dystrophy (DMD), says its developer, RASRx of Newport Beach, California. The Orphan Drug status is given to therapies intended to prevent and treat rare life-threatening or chronically debilitating conditions that affect no more than five…
Simultaneously inhibiting three proteins can increase muscle mass, a finding that could help those with diseases such as muscular dystrophy and cancer that cause muscle deterioration, an Australian study reports. The study, “Specific targeting of TGF-β family ligands demonstrates distinct roles in the regulation of muscle mass in health and…
On June 20, the Massachusetts-based FSH Society and the FSHD Champions ask everyone to join World FSHD Day to raise awareness for facioscapulohumeral muscular dystrophy (FSHD). FSHD patients, their families and their supporters as well as advocacy organizations will come together to urge a cure for one of…
A former investigational drug initially designed to target cancer was found to have therapeutic potential for Duchenne muscular dystrophy (DMD), according to an article published in the scientific journal Molecular Therapy. The study, “SU9516 Increases α7β1 Integrin and Ameliorates Disease Progression in the mdx Mouse Model of Duchenne…
News
SOS Launches DuchenneConnect Australia, Country’s First Patient Registry for DMD Clinical Trials
Advocates from Save Our Sons Duchenne Foundation (SOS), in partnership with Parent Project Muscular Dystrophy (PPMD), have launched Australia’s first patient-led registry to increase clinical trial recruitment in Duchenne muscular dystrophy (DMD). The initiative was inspired by PPMD’s DuchenneConnect patient registry, which since 2007 has provided data…
Sarepta Therapeutics is recruiting up to 99 boys with Duchenne muscular dystrophy (DMD) to test two new compounds, SRP-4045 and SRP-4053, in a Phase 3 clinical trial. The ESSENCE study is a double-blind, placebo-controlled, multi-center Phase 3 clinical trial (NCT02500381) with an open-label extension period, evaluating the two drugs’…
A gene therapy treatment may restore the genetic mutations of myotubular myopathy, a type of muscular dystrophy that affects the skeletal muscles. In a previous study, a team of researchers at the University of Washington School of…
A new clinical-stage biotech, Myonexus Therapeutics, is developing gene therapies for limb-girdle muscular dystrophies (LGMDs). Launch plans include the accelerated development of five investigational gene therapies that have the potential to become the first standard-of-care therapies for LGMDs. Myonexus’ pipeline includes three clinical-stage gene therapy programs (LGMD2E, LGMD2D, and…
Recent Posts
- Talking with my daughter about her journey with DMD carrier status
- Companies join forces to speed production of 1-time treatment for FSHD
- One way to process loss is by advocating for lasting change
- European regulators back new DMD gene therapy with key status
- I am watching a child lose his independence for the third time